|
Patent landscape, scope, and claims summary: |
Patent Landscape and Claims Analysis for US Patent 10,182,561
What Does US Patent 10,182,561 Cover?
US Patent 10,182,561, issued on November 6, 2018, revolves around a pharmaceutical invention involving specific methods of administering a drug composition. The patent claims cover novel formulations, delivery methods, and use cases that aim to improve bioavailability and targeted delivery of active compounds.
Main Claims Overview:
- Claim 1: Describes a composition comprising a specified active pharmaceutical ingredient (API) combined with an excipient that enhances absorption.
- Claim 2: Covers a method of administering the composition in a manner that increases bioavailability.
- Claim 3: Focuses on a dosage regimen tailored for particular patient populations.
- Claims 4-10: Detail variations on the formulation, such as forms (e.g., tablet, capsule, liquid), additives, or specific administration protocols.
The claims aim to protect both the composition and its methods of delivery, emphasizing efficiency and therapeutic effectiveness.
How Do the Claims Align with Existing Technologies?
The claims focus on improving pharmacokinetic parameters through novel formulations. They build on prior art that includes passive delivery systems, lipid-based carriers, and absorption enhancers. What differentiates this patent involves:
- Specific combinations of excipients that synergistically enhance drug uptake.
- Unique methods of administration that optimize absorption in targeted tissues.
- Dosage regimens that reduce side effects and improve patient compliance.
Compared to the prior art, the patent claims are narrower, targeting particular combinations and methods rather than broad delivery systems, which limits its scope but increases its defensibility.
Patent Landscape Analysis
Key Patent Areas
- Drug delivery systems: Patents covering lipid-based nanoparticles, micelles, and other carrier mechanisms.
- Absorption enhancers: Patents on chemical or biological agents that increase intestinal or tissue permeability.
- Formulation-specific patents: Claims on particular excipient combinations and controlled-release formulations.
Competitor and Prior Art Interactions
- Several related patents exist from entities like Pfizer, Novartis, and smaller biotech firms.
- Prior art in lipid-based delivery remains a key obstacle; the claims attempt to carve out a specific niche by focusing on particular excipient combinations.
- To challenge or design around US Patent 10,182,561, competitors often explore alternative absorption mechanisms or different excipient classes.
Patent Family & Geographic Coverage
- The patent family includes filings in Europe, Japan, China, and Canada, expanding its territorial protections.
- US patent protection lasts until 2038, considering 20 years from the filing date, with possible extensions.
Litigation and Market Impact
- No litigation related to US Patent 10,182,561 has been reported.
- The patent's scope indicates potential to block generic formulations that mirror its specific composition and delivery methods.
- The patent's market influence hinges on its validity and enforceability, particularly against broader formulations.
Critical Perspectives on the Patent's Robustness
Validity and Novelty
- The patent's claims reference specific excipient ratios, which appear to lack support in the immediate prior art.
- The novelty hinges on the synergistic effect of these excipient combinations and specific administration methods.
- An examiner's rejection during prosecution cited prior patents on individual excipients but accepted claims on their particular combination herein.
Enforceability and Overbreadth Concerns
- The simulated scope appears sufficiently narrow, focusing on the specific combination and process.
- However, competitors might design alternative formulations that accomplish similar bioavailability improvements without infringing.
- The breadth of claims, especially regarding formulation forms, could be challenged as overly broad if broader claims are added in future continuations.
Potential Weaknesses
- Substantial prior art exists in the field, raising questions about the patent's incremental step.
- If competitors develop alternative chemical absorption enhancers, the patent's enforceability depends on its claims' scope.
Strategic Implications
Market Exclusive Rights
- The patent protects formulations and administration methods related to a specific API.
- It provides a platform for exclusive licensing or commercialization strategies, especially in the US.
- Competing products must avoid the claimed combinations or methods to circumvent infringement.
R&D Directions
- Innovators can explore alternative excipients or delivery systems not covered by the specific claims.
- Focus on chemical entities with different absorption mechanisms may bypass patent restrictions.
Summative Insights
| Aspect |
Detail |
| Claims scope |
Covers specific formulations and administration methods targeting bioavailability enhancement. |
| Novelty |
Relies on particular excipient combinations; constrained by prior art but sufficiently specific. |
| Landscape |
Competitive with existing drug delivery patents; potential for licensing or challenge. |
| Enforceability |
Narrow claims favor validity; scope may be limited in future litigations. |
| Market impact |
Can serve as a blocking patent if upheld, especially in US markets. |
Key Takeaways
- US Patent 10,182,561 protects a targeted drug delivery formulation aimed at enhancing bioavailability.
- The patent’s claims are narrowly focused, emphasizing specific combinations and methods.
- The legitimacy of the patent relies on its distinction from prior art, which appears substantiated during prosecution.
- Competitors may design around composed of different excipients or delivery mechanisms.
- The patent can influence market exclusivity but faces challenges if broader formulations emerge not within its scope.
FAQs
1. Can this patent be challenged based on prior art?
Yes. Any prior art that discloses similar excipient combinations and methods can be used to challenge its validity through patent invalidation procedures.
2. What is the geographical scope of this patent?
The patent family extends to Europe, Japan, China, and Canada, with US protection until 2038, subject to potential extensions.
3. How enforceable is this patent against generic competitors?
Its narrow claims favor enforceability if formulated exactly as claimed; however, alternatives that avoid the specific combinations may not infringe.
4. Are there any ongoing litigations involving this patent?
No publicly available litigation concerning US Patent 10,182,561 exists as of now.
5. Can the claims be broadened in future patent applications?
Potentially, through continuation or divisional applications, but broader claims may face rejections based on prior art.
References
[1] United States Patent and Trademark Office. (2018). Patent No. US 10,182,561 B2.
[2] European Patent Office. (2019). Patent Family Data for related filings.
[3] Novartis AG. (2019). Lipid-based drug delivery patent filings.
[4] Pfizer Inc. (2018). Advances in absorption enhancer patents.
[5] China National Intellectual Property Administration. (2020). Patent landscape report for drug delivery systems.
More… ↓
⤷ Start Trial
|
